Mallinckrodt Pharmaceuticals Generics has entered into a strategic alliance with Zydus Cadila's US subsidiary, Zydus Pharmaceuticals Inc. The agreement calls for Mallinckrodt Pharmaceuticals Generics to market and sell products under a shared Mallinckrodt-Zypharma label. The products will be developed and registered by Zydus Pharmaceuticals and will be manufactured by Zydus Cadila at its US FDA-approved manufacturing plant in Ahmedabad, India.
By melding Mallinckrodt's marketing and distribution networks with Zydus Cadila's product development and manufacturing success, Mallinckrodt expands its product portfolio and pipeline.
Although the annual HIV diagnosis rate between 2010 and 2014 decreased for black individuals by 16.2%, blacks remain disproportionately affected by HIV/AIDS.
Clinical features with downloadable PDFs